Clinical Trial Update: A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics [Phase 1]

View source ↗

Summary

Phase I study of TQ-B3395 evaluating tolerance and pharmacokinetics in patients with advanced cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• TQ-B3395

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Cancer | Phase 1 | Status: TERMINATED